CAMBRIDGE, Mass., May 10, 2016 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today reported financial results for the first quarter ended March 31, 2016. Total net revenues for the quarter ended March 31, 2016 were approximately $14.1 million and included approximately […]